37.52
Novo Nordisk Adr (NVO) 最新ニュース
Novo Nordisk Leans Into Obesity Care With ORION Data And Wegovy Pricing - Sahm
NVO Stock Quote Price and Forecast - CNN
NVO Forecast, Price Target & Analyst Ratings | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales - Benzinga
Novo Nordisk Wins EU Nod To Ease Wegovy Injection Delivery - Sahm
Novo Nordisk A/ S stock: Why it's still a powerhouse amid volatility - AD HOC NEWS
NVO News | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk (NYSE: NVO) details progress in DKK 15B buyback - Stock Titan
Novo Nordisk A/ S stock: Weight-loss boom far from over — what investors need to know - AD HOC NEWS
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus - Sahm
NVO Stock Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S Stock: Navigating GLP-1 Leadership Amid Evolving Obesity Treatment Landscape - AD HOC NEWS
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Sahm
Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan
Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - AD HOC NEWS
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm
Novo Nordisk A/S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recover - AD HOC NEWS
Novo Nordisk A/S Stock: Recent AGM Resolutions Reinforce Dual-Class Structure and Dividend Strength - AD HOC NEWS
Novo Nordisk A/S stock faces pressure amid shifting obesity drug landscape and analyst hold rating - AD HOC NEWS
Novo Nordisk A/S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating h - AD HOC NEWS
Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - AD HOC NEWS
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Sahm
Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS
Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS
Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS
Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS
FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm
Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - sahmcapital.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Finansavisen
大文字化:
|
ボリューム (24 時間):